Advanced

Effect of short-term, low-dose treatment with tamoxifen in patients with primary dysmenorrhea

Pierzynski, Piotr ; Swiatecka, Jolanta ; Oczeretko, Edward ; Laudanski, Piotr ; Batra, Satish LU and Laudanski, Tadeusz (2006) In Gynecological Endocrinology 22(12). p.698-703
Abstract
Current treatment of painful periods and other symptoms related to primary dysmenorrhea (PD) is usually commenced with non-steroidal anti-inflammatory drugs or oral contraceptives, which fails in about 10% of affected patients. Tamoxifen, a selective estrogen-receptor modulator (SERM), has been demonstrated to directly inhibit uterine contractions, causing improvement in uterine blood flow. It could be considered for application in selected groups of dysmenorrheic patients, for instance carriers of breast cancer-associated antigen (BRCA) genes, breast cancer survivors or women with advanced endometriosis. Thus the aim of the present study was to investigate the effect of short-term treatment with tamoxifen on PD and PD-related symptoms, as... (More)
Current treatment of painful periods and other symptoms related to primary dysmenorrhea (PD) is usually commenced with non-steroidal anti-inflammatory drugs or oral contraceptives, which fails in about 10% of affected patients. Tamoxifen, a selective estrogen-receptor modulator (SERM), has been demonstrated to directly inhibit uterine contractions, causing improvement in uterine blood flow. It could be considered for application in selected groups of dysmenorrheic patients, for instance carriers of breast cancer-associated antigen (BRCA) genes, breast cancer survivors or women with advanced endometriosis. Thus the aim of the present study was to investigate the effect of short-term treatment with tamoxifen on PD and PD-related symptoms, as well as its direct effect on parameters of intrauterine pressure during the painful menstruation, in a group of dysmenorrheic patients. After two cycles of administration of tamoxifen we noted a significant decrease in bleeding together with reductions in the severity of menstrual cramps, diarrhea, headache, fatigue and anxiety. In intrauterine pressure assessments, tamoxifen significantly decreased propagation of uterine contractions. In conclusion, SERMs such as tamoxifen may constitute a therapeutic option in selected groups of patients, improving dysmenorrheic symptoms. Additionally to its receptor-mediated effects, tamoxifen was shown to exert a direct influence on uterine contractile activity that may explain the decrease of menstrual pain and cramps noted in the studied group. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
contractility, uterus, dysmenorrhea, tamoxifen, intrauterine pressure
in
Gynecological Endocrinology
volume
22
issue
12
pages
698 - 703
publisher
Informa Healthcare
external identifiers
  • wos:000243829300008
  • scopus:33845678568
ISSN
0951-3590
DOI
10.1080/09513590601030233
language
English
LU publication?
yes
id
94d137e9-7f8b-4937-9d43-21c023653333 (old id 676288)
date added to LUP
2016-04-01 11:37:20
date last changed
2020-01-12 08:16:41
@article{94d137e9-7f8b-4937-9d43-21c023653333,
  abstract     = {Current treatment of painful periods and other symptoms related to primary dysmenorrhea (PD) is usually commenced with non-steroidal anti-inflammatory drugs or oral contraceptives, which fails in about 10% of affected patients. Tamoxifen, a selective estrogen-receptor modulator (SERM), has been demonstrated to directly inhibit uterine contractions, causing improvement in uterine blood flow. It could be considered for application in selected groups of dysmenorrheic patients, for instance carriers of breast cancer-associated antigen (BRCA) genes, breast cancer survivors or women with advanced endometriosis. Thus the aim of the present study was to investigate the effect of short-term treatment with tamoxifen on PD and PD-related symptoms, as well as its direct effect on parameters of intrauterine pressure during the painful menstruation, in a group of dysmenorrheic patients. After two cycles of administration of tamoxifen we noted a significant decrease in bleeding together with reductions in the severity of menstrual cramps, diarrhea, headache, fatigue and anxiety. In intrauterine pressure assessments, tamoxifen significantly decreased propagation of uterine contractions. In conclusion, SERMs such as tamoxifen may constitute a therapeutic option in selected groups of patients, improving dysmenorrheic symptoms. Additionally to its receptor-mediated effects, tamoxifen was shown to exert a direct influence on uterine contractile activity that may explain the decrease of menstrual pain and cramps noted in the studied group.},
  author       = {Pierzynski, Piotr and Swiatecka, Jolanta and Oczeretko, Edward and Laudanski, Piotr and Batra, Satish and Laudanski, Tadeusz},
  issn         = {0951-3590},
  language     = {eng},
  number       = {12},
  pages        = {698--703},
  publisher    = {Informa Healthcare},
  series       = {Gynecological Endocrinology},
  title        = {Effect of short-term, low-dose treatment with tamoxifen in patients with primary dysmenorrhea},
  url          = {http://dx.doi.org/10.1080/09513590601030233},
  doi          = {10.1080/09513590601030233},
  volume       = {22},
  year         = {2006},
}